
SYRE Stock Forecast & Price Target
SYRE Analyst Ratings
Bulls say
Spyre Therapeutics is poised to experience significant growth as it advances multiple anti-TL1A antibodies through clinical trials, with promising results in UC and potential for combination therapy. The company's platform trial and diverse pipeline highlight its potential for success in addressing the unmet need for innovative treatments in IBD and other immune-mediated diseases. Additionally, its strategic approach to co-formulating mAbs with existing drugs could lead to a competitive advantage and higher market demand. With a current valuation of $98 per share based on SOTP analysis, Spyre Therapeutics presents a compelling investment opportunity in the biotechnology sector.
Bears say
Spyre Therapeutics is in the clinical stages of developing treatments for inflammatory bowel diseases and rheumatic diseases with potential to be best-in-class due to their extended half-life antibodies and multiple targeted MOAs. However, with a risk of unexpected outcomes and a lack of established class leaders in the market, the company faces hurdles in achieving commercial success especially in the competitive markets for its product candidates, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SYRE Analyst Forecast & Price Prediction
Start investing in SYRE
Order type
Buy in
Order amount
Est. shares
0 shares